MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.healun.2022.06.001

Медицинская библиотека · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022

Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation.

Vicaire Hugues, Pavec Jérôme Le, Mercier Olaf, Montani David, Boucly Athénaïs, Roche Anne, Pradère Pauline, Dauriat Gaëlle, Feuillet Severine, Pichon Jérémie, Jevnikar Mitja, Beurnier Antoine, Jaïs Xavier, Fadel Elie, Sitbon Olivier, Humbert Marc, Savale Laurent

СтатьяПеревод в очереди

Аннотация

BACKGROUND

It is unknown whether pulmonary arterial hypertension (PAH) risk stratification instruments could be helpful to support the decision to list a patient for lung transplantation (LT). Our aim was to evaluate contemporary risk assessment tools in a cohort of PAH patients listed for LT.

METHODS

Consecutive PAH patients (without pulmonary veno-occlusive disease or unrepaired congenital heart disease) listed for LT at the French Pulmonary Hypertension Reference Center between January 2006 and December 2018 were included. At the time of listing, risk stratification was assessed using the ESC/ERS criteria, the REVEAL Lite 2 score and the COMPERA 2.0 method. The primary end point was overall survival after LT listing. Secondary outcome measures were mortality on waiting list and posttransplant survival.

RESULTS

One hundred and two patients were enrolled (mean age 38 ± 13 years, 69% females). Overall survival after listing was 72%, 58% and 46% at 1, 3 and 5 years respectively. Survival after LT listing was lower in "high-risk" patients according to the ESC/ERS criteria (p = 0.0001) and the REVEAL Lite 2 score (p = 0.04). The COMPERA 2.0 method discriminated post-listing survival of patients at high-risk, intermediate-high and intermediate-low risk (p = 0.04). The proportion of patients requiring urgent transplantation and extracorporeal life support as a bridge to transplantation was higher in the "high-risk" patients. Posttransplant survival was significantly lower in "high-risk" patients according to the ESC/ERS criteria (p = 0.0004).

CONCLUSIONS

High-risk PAH patients at the time of LT listing have poor outcomes, suggesting that LT should be considered earlier in the course of PAH remaining refractory to triple combination therapy with a parenteral prostacyclin.

Для цитирования: Vicaire Hugues, Pavec Jérôme Le, Mercier Olaf, Montani David, Boucly Athénaïs, Roche Anne, Pradère Pauline, Dauriat Gaëlle, Feuillet Severine, Pichon Jérémie, Jevnikar Mitja, Beurnier Antoine, Jaïs Xavier, Fadel Elie, Sitbon Olivier, Humbert Marc, Savale Laurent. Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation.. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2022. DOI: 10.1016/j.healun.2022.06.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.